Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Also, Alnylam wins an important approval for ATTR-CM. The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to ...

While there are RNAi products on the marketplace ... In 2019 results were published in Nature Biotechnology of the research findings, which were described by Secor as “unprecedented and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

A new part of an ocean plant cell has been discovered that might revolutionize farming one day. The structure can take nitrogen and convert it into the ingredient that helps all organisms grow.

Hanks — a journalist, and yes, also the daughter of Tom — recalls driving the highway 10 across the southwest as she tries to make sense of her unstable upbringing and the life and death of ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Welcome to the 3 rd Annual RNAi – Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics Built with biopharmaceutical industry insights, this in person conference will ...